JPRN-UMIN000028628已完成未知
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan - A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma
Bristol-Myers Squibb0 个研究点目标入组 82 人开始时间: 2017年8月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •-Patients enrolled in any clinical trials at any time -Overlapping use of nivolumab and ipilimumab
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma - NIBIT-M1EUCTR2010-019356-50-ITIBIT (NETWORK ITALIANO PER LA BIO-IMMUNOTERAPIA DEI TUMORI)
招募中
2 期
A phase II study of ipilimumab, nivolumab, and radiotherapy for advanced NSCLCJPRN-jRCTs021220003Miyauchi Eisaku40
已完成
1 期
A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV MelanomaMelanomaACTRN12617000772347Peter MacCallum Cancer Centre52
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerEUCTR2016-001928-54-DKBristol-Myers Squibb International Corporation489
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code: 10036909Term: Prostate cancer metastatic Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2022-502909-15-00477